septacidin

01/01/2014 - "Moreover, septacidin-killed MCA205 cells protected immunocompetent mice against a re-challenge with living cancer cells of the same type. "
06/01/2000 - "Thus, spicamycin and KRN5500 may be useful for the treatment of myeloid and lymphoid neoplasms."
06/01/2003 - "Phase I and pharmacokinetic study of KRN5500, a spicamycin derivative, for patients with advanced solid tumors."
02/01/2003 - "The spicamycin derivative KRN5500 was considered as a potential anti-cancer agent based on in vitro and preclinical studies. "
01/01/2014 - "Finally, the antineoplastic effects of septacidin on established murine tumors were entirely dependent on T lymphocytes. "

09/13/2002 - "The goal of this study was to examine the effects of synthetic spicamycin derivative, SAN-Gly, on mechanical allodynia in a spared nerve injury animal model of neuropathic pain. "
09/13/2002 - "A water-soluble synthetic spicamycin derivative (San-Gly) decreases mechanical allodynia in a rodent model of neuropathic pain."
04/01/2012 - "A spicamycin derivative (KRN5500) provides neuropathic pain relief in patients with advanced cancer: a placebo-controlled, proof-of-concept trial."
07/01/2003 - "We have previously shown that KRN5500, a derivative of the antibiotic spicamycin, produces a prolonged (7-day), and significant reduction in neuropathic pain, but not nociceptive pain. "
04/01/2012 - "The purpose of the study was to determine safety and efficacy of KRN5500, a novel, spicamycin-derived, nonopioid analgesic agent, in patients with advanced cancer and neuropathic pain of any etiology. "

06/01/2000 - "In this study, we first investigated the differentiation efficacy of spicamycin and KRN5500 in HL-60 and acute promyelocytic leukemia cell line, NB4, and found that low concentrations of both compounds induced differentiation to a small extent in both cell lines, but markedly induced apoptosis in NB4 cells. "

09/13/2002 - "Spicamycin produced a significant reduction in mechanical allodynia for up to 6 weeks. "
09/13/2002 - "The goal of this study was to examine the effects of synthetic spicamycin derivative, SAN-Gly, on mechanical allodynia in a spared nerve injury animal model of neuropathic pain. "
09/13/2002 - "A water-soluble synthetic spicamycin derivative (San-Gly) decreases mechanical allodynia in a rodent model of neuropathic pain."

10/01/2000 - "The effects of KRN5500, a spicamycin derivative, on neuropathic and nociceptive pain models in rats."
07/01/2003 - "We have previously shown that KRN5500, a derivative of the antibiotic spicamycin, produces a prolonged (7-day), and significant reduction in neuropathic pain, but not nociceptive pain. "
10/01/2000 - "We studied the effects of a spicamycin derivative, KRN5500, on two animal models of neuropathic pain (Chung and Bennett models) and a nociceptive pain model by using Complete Freund's adjuvant. "